First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function

SIMPLE SUMMARY: About 40% of people diagnosed with cancer are eligible for treatment with checkpoint inhibitors (CPIs). Little research has been conducted to understand whether CPIs affect cognitive function. Most research that has been conducted included patients who received both CPIs and chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Jamie S., Parks, Adam C., Mahnken, Jonathan D., Young, Kate J., Pathak, Harsh B., Puri, Rajni V., Unrein, Amber, Switzer, Phyllis, Abdulateef, Yazan, Sullivan, Samantha, Walker, John F., Streeter, David, Burns, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000599/
https://www.ncbi.nlm.nih.gov/pubmed/36900405
http://dx.doi.org/10.3390/cancers15051615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000599/
https://www.ncbi.nlm.nih.gov/pubmed/36900405
http://dx.doi.org/10.3390/cancers15051615

Ejemplares similares